An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells

We proved that rasagiline protected dopaminergic SH-SY5Y cells against apoptosis induced by a dopaminergic neurotoxin, N-methyl(R)salsolinol, and the mechanism was clarified to be due to suppression of death signal transduction in mitochondria

Yukihiro Akao; Wakako Maruyama; Hong Yi; Masayo Shamoto-Nagai; Moussa B.H. Youdim; Makoto Naoi

2002

Scholarcy highlights

  • N-Propargyl-1(R)-aminoindan is under phase III clinical trials for Parkinson's disease, and it rescues dopamine neurons from cell death in animal and cellular models of PD
  • We proved that rasagiline protected dopaminergic SH-SY5Y cells against apoptosis induced by a dopaminergic neurotoxin, N-methyl(R)salsolinol, and the mechanism was clarified to be due to suppression of death signal transduction in mitochondria
  • Enhanced expression of bcl-2 family indicates the ability of rasagiline to adjust the apoptotic threshold and protect degenerating neurons in PD

Need more features? Save interactive summary cards to your Scholarcy Library.